Metastatic uveal melanoma (mUM) is a rare disease, and with few effective therapeutic options it is unclear what patients receive as standard of care. Based on national guidelines, we mapped out real-world patient pathways with clinical experts across regional and supra-regional centres across England, to inform a consensus pathway of care following mUM diagnosis.
Adams E, Cheng CY, Sacco J, et. al. Mapping the treatment pathway for metastatic uveal melanoma (mUM) patients in England: A qualitative pilot study. Society for Immunotherapy of Cancer’s 32nd Annual Meeting. 8-10 November 2017, National Harbour, Maryland, USA.